Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial Academic Article 2023

10.1093/cid/ciac827

Overview
Additional Document Info
Otro
Ver todos

authors

L. Waters
J Rockstroh
C. Katlama
GMN Behrens
JM Castell
A Pozniak
E Martínez
BOIX MARTINEZ, VICENTE
NEAT 022 Study Gropul
PORTILLA SOGORB, JOAQUIN
GUTIERREZ RODERO, FELIX
L. Assoumou
A. González Cordón
S. Rusconi
P Domingo
M Gompels
S de Wit
F Raffi
MASIA CANUTO, MARIA DEL MAR

publication date

2023

published in

CLINICAL INFECTIOUS DISEASES Journal